The goal of this program is to develop an improved understanding of metabolic differences between tumors and normal tissue, prior to and after initiation of anti-cancer therapy. The practical objective is to determine how these functional differences lead to useful strategies for differentiating tissues based on biochemical characteristics, and then to learn how this information can be applied for better selection of individualized treatment for a patient. The ultimate goal is to use metabolic imaging information to achieve improved treatment outcome for each patient. Clinical cancer research and tumor biology research are complementary parts of each project. All of the projects investigate ways in which metabolic imaging can contribute to more effective treatment of the patient with cancer, as well as to our understanding of mechanisms by which therapy kills or fails to kill tumors. The projects all use positron emission tomography (PET) to provide quantitative imaging information from the whole body and also data on regional heterogeneity. The team of investigators is strongly interdisciplinary. It draws together experts in oncology, nuclear medicine, radiology, radiobiology, neurology and biochemistry, as well as kinetic modeling, statistics, physics, and radiochemistry. The hypothesis that tumor metabolism is a sensitive measure of response to therapy is a broad one. We have chosen to focus on selected aspects that appear most likely to be important and useful indicators of tumor status and to study patients on several occasions. Some studies look into the deeper levels of cellular energetics, beyond the phosphorylation of FDG (Project 1). Others measure tumor growth at the level of DNA replication (Project 2). The hormonal status of tumors is being characterized (Project 4), as are factors such as oxygenation that influence tumor biology as well as response to therapy (Project 3). Throughout the projects, metabolic imaging measurements are tested as predictors of important aspects of treatment outcome. In addition to providing insight into the metabolic response of a patient receiving standard surgical, drug or radiation therapy, PET imaging will provide human data on mechanisms of response in new cancer treatment strategies. As a result of these studies, metabolic images of regional tumor metabolism done before, during, and long after therapy are providing insight into tumor biology that is helping to select evaluate, and even modify therapy for the individual patient.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA042045-16
Application #
6512367
Study Section
Subcommittee G - Education (NCI)
Program Officer
Torres-Anjel, Manuel J
Project Start
1998-05-12
Project End
2004-02-29
Budget Start
2002-04-17
Budget End
2004-02-29
Support Year
16
Fiscal Year
2002
Total Cost
$1,841,023
Indirect Cost
Name
University of Washington
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Lindner, Jonathan R; Link, Jeanne (2018) Molecular Imaging in Drug Discovery and Development. Circ Cardiovasc Imaging 11:e005355
O'Sullivan, Finbarr; O'Sullivan, Janet N; Huang, Jian et al. (2018) Assessment of a statistical AIF extraction method for dynamic PET studies with 15O water and 18F fluorodeoxyglucose in locally advanced breast cancer patients. J Med Imaging (Bellingham) 5:011010
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Link, Jeanne M; Krohn, Kenneth A; O'Hara, Matthew J (2017) A simple thick target for production of89Zr using an 11MeV cyclotron. Appl Radiat Isot 122:211-214
Wolsztynski, E; O'Sullivan, F; O'Sullivan, J et al. (2017) Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. Stat Med 36:1172-1200
Kurland, Brenda F; Peterson, Lanell M; Lee, Jean H et al. (2017) Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res 23:407-415
Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2017) A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. Phys Med Biol 62:3639-3655
Fowler, Amy M; Clark, Amy S; Katzenellenbogen, John A et al. (2016) Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med 57 Suppl 1:75S-80S
Muzi, Mark; Krohn, Kenneth A (2016) Imaging Hypoxia with ยน?F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis. J Nucl Med 57:497-8
Currin, Erin; Peterson, Lanell M; Schubert, Erin K et al. (2016) Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. J Natl Compr Canc Netw 14:144-7

Showing the most recent 10 out of 196 publications